Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2025

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of March 31, 2025 and December 31, 2024 were as follows:


	March 31, 2025		December 31, 2024
Accrued research and development	$	2,261,002	$	2,664,065
Accrued compensation expenses		20,999		537,630
Accrued professional fees		208,667		36,360
Other accounts payable and accrued expenses		3,394		4,787
Total	$	2,494,062	$	3,242,842